Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
Open Access
- 7 October 2022
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 62 (9) , 1143-1147
Abstract
Objective: This prospective cohort, real‐life study aimed to evaluate whether galcanezumab, a monoclonal antibody anti‐calcitonin gene‐related peptide (CGRP) ligand, can reduce caregivers' distress and improve their mutuality with patients. Background: Migraine is a highly disabling chronic disease that negatively impacts patients' and often their relatives' lives, occurring during an active phase of life with direct consequences on leisure‐ and work‐related activities. The figure of caregiver is crucial in several neurological conditions but poorly accounted for in migraine care so far. Studies on monoclonal antibodies against the CGRP pathway, recently introduced as migraine‐preventive treatments, demonstrated that they significantly reduce migraine frequency and disability in the first weeks of treatment. Methods: Consecutive patient‐caregiver dyads were evaluated at baseline and after 6 months of treatment with galcanezumab (V6) at our headache center from September 2020 to September 2021. Enrolled patients were requested to report their monthly migraine days, monthly intake of acute medications, attack pain intensity (on the Numeric Rating Scale), concomitant preventives, and disability questionnaires (Headache Impact Test, Migraine Disability Assessment). Each dyad filled in the Mutuality Scale to check their reciprocity; moreover, the Relatives' Stress Scale was used to detect caregivers' distress. Results: We enrolled 27 patient‐caregiver dyads. At 6 months, migraine burden significantly improved with reductions in monthly migraine days (falling from 14.8 [SD = 4.8] days by 10.3 [SD = 4.8] days; 95% CI: 8.4, 12.2; p < 0.001) and Migraine Disability Assessment scores (lowering from 83.6 [SD = 46.7] by 71.5 points [SD = 49.3]; 95% CI: 51.2, 91.9; p < 0.001). From baseline to month 6, the caregiver Relatives' Stress Scale score significantly decreased (falling from 20.7 [SD = 13.7] by 6.5 [SD = 14.1] points; 95% CI: 0.8, 12.2; p = 0.027), while the Mutuality Scale's caregiver total score increased (from 3.04 [SD = 0.61] by 0.29 [SD = 0.49] points; 95% CI: −0.508, −0.064; p = 0.014). Conclusions: Our findings preliminarily demonstrated that patients' migraine improvement after 6 months of galcanezumab treatment could be favorably perceived by caregivers, significantly reducing their distress with better reciprocity within the dyad.Keywords
This publication has 26 references indexed in Scilit:
- Psychometric Characteristics of the Mutuality Scale in Stroke Patients and CaregiversThe Gerontologist, 2016
- The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline resultsCephalalgia, 2014
- The impact of headache in Europe: principal results of the Eurolight projectThe Journal of Headache and Pain, 2014
- Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia, 2010
- Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptomsJournal of Neurology, Neurosurgery & Psychiatry, 2007
- High score on the Relative Stress Scale, a marker of possible psychiatric disorder in family carers of patients with dementiaInternational Journal of Geriatric Psychiatry, 2006
- Physical and Psychosocial Health in Family Caregiving: A Comparison of AIDS and Cancer CaregiversPublic Health Nursing, 2004
- Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase IIICurrent Medical Research and Opinion, 2004
- Mutuality and preparedness as predictors of caregiver role strainResearch in Nursing & Health, 1990
- MEASURING BEHAVIOURAL DISTURBANCE OF ELDERLY DEMENTED PATIENTS IN THE COMMUNITY AND ITS EFFECTS ON RELATIVES: A FACTOR ANALYTIC STUDYAge and Ageing, 1982